We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Charles River's (CRAI) Forensic Services Practice Gets New VP
Read MoreHide Full Article
Charles River Associates (CRAI - Free Report) yesterday announced the appointment of Daniel Roffman as a vice president at its Forensic Services Practice.
Roffman specializes in helping clients protect their most valuable information and investigating allegations of trade secret theft and cyber incidents. He has vast expertise in testifying on behalf of plaintiffs and defendants, and has served as a court-appointed neutral expert on trade secret cases. He has also testified on a range of other digital forensic subjects, including software piracy, cyber investigations and electronic document authenticity issues. Earlier, he had worked as a senior managing director at an international consulting firm where he monitored the company’s digital forensic staff and oversaw operations at their U.S. forensic laboratories. He had also worked in the High Technology Investigations Unit of the Criminal Division of the U.S. Department of Justice.
Considering Roffman’s more than 20 years of experience in the digital forensics and information security consulting space, the latest appointment is expected to strengthen Charles River’s competitive position.
Paul Maleh, the company’s president and chief executive officer, stated, "We’re excited to have Dan on board. He will enhance our strong team of experts who regularly lead high-stakes cyber and theft of trade secret investigations, and who credibly testify about their findings when required."
Kris Swanson, Forensic Services Practice leader stated, "As our clients’ information security risks continue to grow exponentially, we are thrilled to be able to add Dan’s global expertise to our team."
So far this year, shares of Charles River have gained 57.6% compared with 10.4% rise of the industry it belongs to.
The long-term expected earnings per share (three to five years) growth rate for Gartner, Equifax and TransUnion is 13.5%, 14% and 20.9%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Charles River's (CRAI) Forensic Services Practice Gets New VP
Charles River Associates (CRAI - Free Report) yesterday announced the appointment of Daniel Roffman as a vice president at its Forensic Services Practice.
Roffman specializes in helping clients protect their most valuable information and investigating allegations of trade secret theft and cyber incidents. He has vast expertise in testifying on behalf of plaintiffs and defendants, and has served as a court-appointed neutral expert on trade secret cases. He has also testified on a range of other digital forensic subjects, including software piracy, cyber investigations and electronic document authenticity issues. Earlier, he had worked as a senior managing director at an international consulting firm where he monitored the company’s digital forensic staff and oversaw operations at their U.S. forensic laboratories. He had also worked in the High Technology Investigations Unit of the Criminal Division of the U.S. Department of Justice.
Considering Roffman’s more than 20 years of experience in the digital forensics and information security consulting space, the latest appointment is expected to strengthen Charles River’s competitive position.
Paul Maleh, the company’s president and chief executive officer, stated, "We’re excited to have Dan on board. He will enhance our strong team of experts who regularly lead high-stakes cyber and theft of trade secret investigations, and who credibly testify about their findings when required."
Kris Swanson, Forensic Services Practice leader stated, "As our clients’ information security risks continue to grow exponentially, we are thrilled to be able to add Dan’s global expertise to our team."
So far this year, shares of Charles River have gained 57.6% compared with 10.4% rise of the industry it belongs to.
Zacks Rank and Other Stocks to Consider
Charles River currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some other top-ranked stocks in the broader Zacks Business Servicessector are Gartner (IT - Free Report) , Equifax (EFX - Free Report) and TransUnion (TRU - Free Report) , each carrying a Zacks Rank #2.
The long-term expected earnings per share (three to five years) growth rate for Gartner, Equifax and TransUnion is 13.5%, 14% and 20.9%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>